Consequences of the new Reimbursement Act for patients and the public payer

Authors

Józef Haczyński, Doktor habilitowany nauk medycznych; Centrum Zarządzania w Ochronie Zdrowia, Wydział Zarządzania, Uniwersytet WarszawskiFollow
Zofia Skrzypczak, Doktor; Centrum Zarządzania w Ochronie Zdrowia, Wydział Zarządzania, Uniwersytet WarszawskiFollow

Keywords

Drug expenses, reimbursement, patients contribution

Abstract

The Act on the Reimbursement of Medicines, Foodstuffs Intended for Particular Nutritional Uses and Medical Devices came into force on 1 January 2012. Its purpose was to transform the Polish medicine reimbursement so that the available public funds corresponded as closely as possible to the current social needs in the supply of refunded products. The consequence of the new reimbursement act – experienced painfully by patients - was a decrease in the share of reimbursement (and thus increase in patients’ contribution) in the value of the purchased medicine on prescription (Rx).

Recommended Citation

Haczyński, J., & Skrzypczak, Z. (2016). Consequences of the new Reimbursement Act for patients and the public payer. internetowy Kwartalnik Antymonopolowy i Regulacyjny (internet Quarterly on Antitrust and Regulation), 5(8), 93-103. https://doi.org/10.7172/2299-5749.IKAR.8.5.7

First Page

93

Last Page

103

Page Count

10

DOI

10.7172/2299-5749.IKAR.8.5.7

Publisher

University of Warsaw